News
MHLW (Japan) regulatory approval for Mitchga, the first antibody targeting IL-31 for itching associated with atopic dermatitis.
Chugai Pharmaceutical announced that Maruho Co. obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for the anti-IL-31 receptor A humanized monoclonal antibody Mitchga Subcutaneous Injection 60 mg Syringes [generic name: nemolizumab (genetical recombination)] for the treatment of itching associated with atopic dermatitis (only when existing treatment is insufficiently effective).
The approval is based on the results from a Japanese phase III clinical study in patients with moderate to severe AD who are older than 13 years old and are tolerant to existing treatments.
Condition: Atopic Dermatitis (Eczema)
Type: drug